Paul Conley

We envision a world where we continuously, sustainably, and affordably improve human life with biocatalysis. Our proprietary platform of engineered enzymes and our unique manufacturing approach enables the production of thousands of amino acids that were previously too difficult and expensive to make. Our noncanonical amino acids are catalyzing the creation of revolutionary and innovative products that are good for people and the planet.

Partillion Bioscience is an early stage life science company aiming to democratize advanced single-cell assays with its award-winning nanovial platform. Our novel platform allows the rapid compartmentalization and analysis of millions of single cells to probe biological function such as secreted proteins. The validated technology underpinning Partillion’s products has been featured in notable journals such as Science Advances, Advanced Functional Materials, and Lab on Chip and received industry accolades, winning the 2020 SLAS Innovation Award.

Attune Neurosciences is a clinical-stage medical device company dedicated to improving human health and performance through clinically-proven, non-invasive neurostimulation products.

With the power to skillfully write meaningful DNA sequences, we embark on a new era where precise control over biology and the manipulation of matter in our environment is possible. Constructive Biology is a spin out from the laboratory of Prof. Jason Chin at the MRC Laboratory of Molecular Biology in Cambridge. Our platform allow us to fundamentally reprogram the genetic code, and make molecules that nature could not make before. We will use our technologies to biosynthesize new classes of enzymes, pharmaceuticals and biomaterials. If you would like to join our team, get in touch!

Alida Biosciences is developing the next generation of RNA analysis tools to enable new medical treatments and diagnostic assays.

Edifice Health is a digital health spin-out company from a 10-year Stanford research in human immunology offering a novel metric of inflammatory health. The inflammatory health measure is then augmented with personalized health interventions to improve and extend healthspan. Edifice has solid underpinnings in immunological science and in AI-powered technology. It will combine these proprietary elements with a consumer and market-centric orientation to deliver on its mission in tackling chronic diseases worldwide. http://med.stanford.edu/1000immunomes.html

Nortis is a privately held Organs-on-Chip company that is revolutionizing traditional drug development and discovery processes. Nortis currently works with biopharma leaders and top academic centers like the University of Washington, Fred Hutchinson Cancer Research Center and Massachusetts Institute of Technology (MIT). For more information about Nortis visit www.nortisbio.com. Organs-on-Chip is a rapidly emerging field in the life sciences market - it covers the engineering of living human tissues within microfluidic devices called chips. Nortis'​ groundbreaking ParVivo system aims to provide powerful alternatives to the use of laboratory animals in the pharmaceutical industry, academic research and the cosmetics industry. Currently there is a gap between the following: in-vitro modeling, in-vivo testing and clinical results. Two dimensional models do not allow the biology to respond in a manner that it would in-vivo, and animal testing often does not correlate with human responses. By growing tissue from human organ systems inside small microfluidic chips, researchers and assay developers can conduct in-vitro testing directly on functional human tissues. One example is the proximal tubule of the human kidney, which has been shown in many cases to be more sensitive to drug side effects than animal kidneys. Other tissue models that Nortis and our collaborators have developed on the ParVivo system include brain, heart, liver, immune system, blood vessels, and cancer applications.

We are accelerating drug discovery to deliver treatments to patients faster. Our powerful engine integrates combinatorial chemistry, pico-scale activity-based screening, and AI, generating millions of empirical datapoints every week to evolve our models. This enables our biologists and medicinal chemists to discover novel small molecule therapeutics rapidly.

We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our first clinical development programme is researching investigational COMP360 psilocybin treatment for patients with treatment-resistant depression. We want to transform the patient experience in mental health care.

Mythic Therapeutics is a product-platform company that is pioneering a powerful new approach to improving the effectiveness of antibody-drug conjugates (ADCs) and other antibody-based therapeutics. Our technology dramatically increases therapeutic potency without compromising safety, thereby unlocking the full potential of targeted therapies against a broad array of tumor targets. At Mythic, we focus on patient-centered science and are driven to leave a lasting impact on cancer care.

Tasso is a fast-growing Seattle-based startup focused on delivering at-home diagnostic testing to those who need it most. We are growing our footprint with leading health systems, clinical research organizations, academic medical centers, and more who are looking to deliver clinical-grade, convenient diagnostic tests to their patients. Tasso was originally founded to find a better way to collect blood instead of a painful fingerstick or time-consuming venous draw. Since then, our products have been used in pharmaceutical clinical trials, by Olympians as part of a new virtual anti-doping program, and broadly by hospital systems across the US.

Founded in 2017, RubrYc Therapeutics, Inc., has created novel computational tools, chemical libraries, and analytics that confer distinct competitive advantages in the discovery of biotherapeutics. Protein interactions are the critical nodes in physiology. RubrYc has invented a unique approach, based on molecular engineering principles, to modulate therapeutically relevant protein interactions using our Interface Discovery Engine™. We integrate massively parallel in silico simulation and empirical analyses of protein structures to address long-standing challenges in biotherapeutic discovery. In therapeutic antibody discovery, epitopes matter. Our platform enables a non-conventional approach that uniquely enriches discovery campaigns with therapeutic antibody candidates that are on target, on epitope, and optimized for the prescribed mode of action. Our unique insights into protein interactions provide unprecedented opportunities to modulate historically challenging protein interactions, and access to emerging/novel targets. RubrYc Therapeutics emerged as a spin-out from HealthTell, Inc. in April 2018, announcing its rational design approach to biotherapeutic discovery using the Interface Discovery Engine. RubrYc also announced it has partnered with Third Point Ventures, iCarbonX, Paladin Capital, and Vital Venture Capital to to finance launch and initial operations.

Delix Therapeutics is applying modern tools of pharmaceutical development to some of natures most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a new class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. Delix is rapidly advancing these psychoplastogen compounds through preclinical and clinical development, with the goal of one day alleviating mental suffering through its FDA-approved, take-home medicines.

Cyberhedge is a Financial Services firm specializing in Managing Technology Risk. We empower Stakeholders and Executives with in depth financial evidence when it comes to reporting on technology risk. We have offices located in Washington DC, New York, and Luxembourg.

We envision a world where we continuously, sustainably, and affordably improve human life with biocatalysis. Our proprietary platform of engineered enzymes and our unique manufacturing approach enables the production of thousands of amino acids that were previously too difficult and expensive to make. Our noncanonical amino acids are catalyzing the creation of revolutionary and innovative products that are good for people and the planet.

Partillion Bioscience is an early stage life science company aiming to democratize advanced single-cell assays with its award-winning nanovial platform. Our novel platform allows the rapid compartmentalization and analysis of millions of single cells to probe biological function such as secreted proteins. The validated technology underpinning Partillion’s products has been featured in notable journals such as Science Advances, Advanced Functional Materials, and Lab on Chip and received industry accolades, winning the 2020 SLAS Innovation Award.

Attune Neurosciences is a clinical-stage medical device company dedicated to improving human health and performance through clinically-proven, non-invasive neurostimulation products.

With the power to skillfully write meaningful DNA sequences, we embark on a new era where precise control over biology and the manipulation of matter in our environment is possible. Constructive Biology is a spin out from the laboratory of Prof. Jason Chin at the MRC Laboratory of Molecular Biology in Cambridge. Our platform allow us to fundamentally reprogram the genetic code, and make molecules that nature could not make before. We will use our technologies to biosynthesize new classes of enzymes, pharmaceuticals and biomaterials. If you would like to join our team, get in touch!